Therapy of Unresectable Hepatocellular Carcinoma

Abstract

Hepatocellular carcinoma is one of the most common malignant tumors in the world. It is a major cause of death from cancer in eastern Asia, especially China, Japan, Taiwan, Singapore, and Korea, and sub-Saharan Africa, particularly Zimbabwe, Ethiopia, and Mozambique.¹ The annual number of deaths worldwide is estimated to exceed 250,000. Although much less common in North America, hepatocellular carcinoma is responsible for approximately 12,000 deaths per year in the United States. About half the patients in the United States have regional or distant spread at the time of diagnosis. The five-year survival rate among white patients increased from 2 . . .